Efficacy and safety of infliximab in Chinese patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2016
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai CP Guojian Pharmaceutical
- 21 May 2012 Actual end date (31 Dec 2009) added as reported by Chinese Clinical Trial Register record.
- 18 Nov 2010 New trial record